CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology ...( Findings Suggest New Way to Stimul...),Health

Findings Suggest New Way to Stimulate the Immune System to Fight Viral

Diseases

VIENNA, Va., June 9 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM) and researchers at Northeastern Ohio Universities Colleges of Medicine and Pharmacy jointly announced favorable new developments in the LEAPS(TM) heteroconjugate vaccine technology developed by CEL-SCI at the FOCIS Immunology meeting in Boston, MA on June 8, 2008. Patricia Taylor, M.S., working with Dr. Ken S. Rosenthal, Professor of Microbiology and Immunology at the Northeastern Ohio Universities Colleges of Medicine and Pharmacy and Dr. Dan Zimmerman, CEL-SCI's Senior Vice President of Research and Cellular Immunology, demonstrated that immunization with a LEAPS (Ligand Epitope Antigen Presentation System) vaccine altered the immunological hormone (cytokine) balance toward a Th1 environment. It has been shown that a Th1 cellular immune response is needed for protection against many viral diseases. Th1 promotes a combination of antibody and cell mediated protective immune responses compared to the antibody producing Th2 environment induced by most vaccines.

Most notably, within three days of immunization with the "J" type LEAPS vaccines, the cytokine that drives a Th1 response, IL-12, and the primary cytokine that mediates its effects, interferon gamma, were detected in the blood. The LEAPS vaccines that were examined include one that was previously shown to provide antigen specific protection and cellular immunity against herpes simplex virus infection via interferon gamma in mouse models of human disease and another that is directed against a HIV protein.

Dr. Zimmermann said: "These findings give us a new way to stimulate the
'/>"/>